The results confirm previous findings suggesting molecular tests may not be the best tool guide treatment for Clostridium difficile infection, and toxin assays are necessary.
Using Quanterix's Simoa technology, the group developed assays to detect C. diff toxins with a high degree of sensitivity and specificity.
The assay is the first on the firm's isothermal nucleic acid amplification-based platform.
The test adds to a growing menu of approved assays for the cobas 4800 system.
Researchers from the Public Health Agency of Sweden have developed an approach for typing Clostridium difficile isolates based on their patterns of high-molecular weight proteins.
Diagnostics revenues at the company jumped 5 percent organically driven in part by a 16 percent increase in sales of illumigene molecular diagnostic products.
The waiver opens up a significant new opportunity for Alere within the physician office market, according to a company executive.
The investment bank downgraded Meridian Bioscience from a prior Market Perform rating, noting challenges to its molecular diagnostics business.
Researchers measure changes in gut microbiome associated with taking proton pump inhibitors and hint at link to C. difficile infection.
The Centers for Disease Control and Prevention estimates more people get sick and die from drug-resistant germs than previously thought, the Washington Post reports.
According to the Associated Press, three universities and a healthcare institution are sharing a gift of $1 billion.
New rules seek to limit the type of scientific and medical research that can be used to guide public health regulations, the New York Times reports.
In Nature this week: FreeHi-C approach simulates Hi-C data from interacting genome fragments, and more.